Key result
This review summarizes the connection between left ventricular hypertrophy and excess cardiovascular morbidity and mortality in patients with chronic kidney disease and end-stage renal disease.
This review summarizes the evidence linking left ventricular hypertrophy and cardiac fibrosis to excess cardiovascular morbidity and mortality in patients with chronic kidney disease and end-stage renal disease.
Recently, new attention has been focused on an increase in left ventricular mass and the attendant cardiac fibrosis as possible substrates for the excess cardiovascular morbidity and mortality seen so frequently in patients with chronic kidney disease and end‐stage renal disease. We provide a summary of the strength of the connection between left ventricular hypertrophy and morbidity and mortality in these patients, examine possible biological mechanisms, and suggest new approaches to its management.
No takes yet. Share an insight, caveat, or question.
Glassock et al. (2010) conducted a review in Chronic kidney disease and end-stage renal disease. Increased left ventricular mass / left ventricular hypertrophy was evaluated on Cardiovascular morbidity and mortality. This review summarizes the connection between left ventricular hypertrophy and excess cardiovascular morbidity and mortality in patients with chronic kidney disease and end-stage renal disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: